Corona Virus
Stay Safe, FollowGuidance
Fetching Location Data…
James Hyerczyk
Asia Pacific Shares

The major Asia-Pacific stock indexes finished mostly higher on Friday with Australia bucking the trend as investors reacted positively to strong industrial profits from China for October. Traders showed little reaction to concerns over the Oxford-AstraZeneca vaccine candidate despite criticisms from U.S. experts on the results and methods used in their phase three vaccine trials.

In the cash market on Friday, Japan’s Nikkei 225 Index settled at 26644.71, up 107.40 or +0.40%. Hong Kong’s Hang Seng Index finished at 26894.68, up 75.23 or +0.28% and South Korea’s KOSPI Index closed at 2633.45, up 7.54 or +0.29%.

In China, the Shanghai Index settled at 3408.31, up 38.57 or 1.14% and Australia’s S&P/ASX 200 Index finished at 6601.10, down 35.30 or -0.53%.

China’s Industrial Profits Grow at Quickest Monthly Pace Since Early 2017

Profits at China’s industrial firms grew in October for a sixth consecutive month and at their quickest pace since early 2017, pointing to a steady recovery in the manufacturing sector after it was hard hit by the COVID-19 pandemic.

Profits at Chinese industrial firms surged 28.2% year-on-year in October to 642.91 billion yuan ($97.79 billion), National Bureau of Statistics (NBS) data showed on Friday, after rising 10.1% in September versus the previous year.


China Stocks End Higher to Post Weekly Gains on Upbeat Data

China stocks rose on Friday to post weekly gains, as upbeat profits from industrial firms pointed to a continued recovery in the world’s second largest economy amid the coronavirus outbreak.

UBS has set a target of 5,450 and 6,300 at end-2021 and end-2022, respectively, for the blue-chip CSI300 Index, adding mainland households could raise exposure to onshore equities in the next two years.

In other news, a spurt of missed debt repayments by three Chinese state-owned firms – a coal miner, a chipmaker and an automobile company – has shaken local markets and heightened speculation that a campaign to wean the economy off heavy credit is back.

South Korea Stocks Gain for Fourth Straight Week on Vaccine Hopes, Exports Outlook

South Korean shares ended higher on Friday, gaining for a fourth straight week, helped by a slew of potentially successful coronavirus vaccines on the table and an upbeat outlook for November exports.

South Korea’s exports likely bounced back in November and are expected to continue recovering for the time being, supported by strong chip sales and global demand, a Reuters poll showed on Friday.

The KOSPI has risen 19.83% so far this year, and gained 11.2% in the previous 30 trading sessions.

Foreigners Net Buyers of Japanese Stocks for Third Week in a Row

Foreign investors remained net buyers of Japanese equities for a third straight week that ended November 20, buoyed by progress in a second coronavirus vaccine-related developments that rekindled hopes of a swift global economic recovery.

Overseas investors were net buyers of stocks worth 597.17 billion yen ($5.74 billion) last week, after purchasing over 1 trillion yen in each of the previous two weeks, data from Japanese exchanges showed.

They bought 333.18 billion yen in cash equities markets and 263.99 billion yen worth of derivatives.

For a look at all of today’s economic events, check out our economic calendar.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.